In a preclinical study, researchers identify differences in intracellular signaling for memantine's lack of antidepressant properties.
With research showing that ketamine, a noncompetitive antagonist of the glutamate N-methyl-D-aspartate (NMDA) receptor, can be a rapidly acting antidepressant, there is clinical and research interest in whether other drugs with similar mechanisms of action, but without ketamine's adverse effects, possess this clinical activity. Memantine is an NMDA receptor antagonist, but does not appear to have rapid antidepressant effects. To explore the clinical discrepancy, researchers recently examined these two drugs' underlying functional differences in NMDA neurotransmission.
In several animal models, ketamine (but not memantine) produced effects indicative of antidepressant properties. In cultured hippocampal neurons, both memantine and ketamine an…
Reviewing Author
DisclosuresRoyaltiesTextbook of Traumatic Brain Injury, 2nd and 3rd editions
Editorial BoardsUpToDate; Journal of Neuropsychiatry and Clinical Neuroscience
Leadership Positions in Professional SocietiesNorth American Brain Injury Association (Board Member); National Institute on Disability, Independent Living, and Rehabilitation Research (Chair of Data Monitoring Safety Board for study of donepezil on cognition after traumatic brain injury)
DisclosuresRoyaltiesTextbook of Traumatic Brain Injury, 2nd and 3rd editions
Editorial BoardsUpToDate; Journal of Neuropsychiatry and Clinical Neuroscience
Leadership Positions in Professional SocietiesNorth American Brain Injury Association (Board Member); National Institute on Disability, Independent Living, and Rehabilitation Research (Chair of Data Monitoring Safety Board for study of donepezil on cognition after traumatic brain injury)